Background: Activation of the RET proto-oncogene, located on the long arms of chromosome 10, contributes to the development of thyroid cancers in two different ways. First, somatic rearrangements of RET with variable activation genes are frequently found in papillary thyroid carcinomas. Second, germ-line point mutations are responsible for the development of medullary thyroid carcinomas and multiple endocrine neoplasia type 2 (MEN 2). There are several conflicting reports on the influences of RET expression and RET/PTC rearrangements on the clinical outcome of thyroid cancers. Therefore, the wild-type RET gene expression and RET/PTC-1, RET/PTC-2, RET/PTC-3 rearrangements were examined in thyroid carcinomas and other thyroid diseases. Materi...
Malignant tumors of the thyroid gland vary considerably in aggressiveness, ranging from a well-diffe...
The RET/PTC oncogene has been isolated almost twenty years ago. During these years, the research has...
PubMed ID: 18393128Objective: In recent years, thyroid cancer has been at the forefront of molecular...
Background: Activation of the RET proto-oncogene, located on the long arms of chromosome 10, contrib...
none6RET/PTC1 and RET/PTC3 are the markers for papillary thyroid carcinoma. Their reported prevalenc...
OBJECTIVE: The activation of RET proto-oncogene, through different types of chromosomal translocatio...
Objective: The activation of RET proto-oncogene, through different types of chromosomal transloca-ti...
OBJECTIVE: RET proto-oncogene rearrangements (ret/PTCs) represent the most common genetic alteration...
The rearranged during transfection (RET) proto-oncogene was identified in 1985 and, very soon therea...
Thyroid carcinoma is the most frequent endocrine cancer accounting for 5-10% of thyroid nodules. Pap...
We have recently reported the activation of a new oncogene in human papillary thyroid carcinomas. Th...
Non-thyroid neoplasia were analysed by Southern blot of genomic DNA and DNA prepared by reverse tran...
RET proto-oncogene rearrangements (RET/PTC) are causative events in the pathogenesis of a subset of ...
Papillary thyroid carcinomas (PTCs) are the most frequent type of malignant thyroid tumors. Somatic ...
Background: The molecular pathogenesis of hereditary medullary thyroid carcinoma is well known to be...
Malignant tumors of the thyroid gland vary considerably in aggressiveness, ranging from a well-diffe...
The RET/PTC oncogene has been isolated almost twenty years ago. During these years, the research has...
PubMed ID: 18393128Objective: In recent years, thyroid cancer has been at the forefront of molecular...
Background: Activation of the RET proto-oncogene, located on the long arms of chromosome 10, contrib...
none6RET/PTC1 and RET/PTC3 are the markers for papillary thyroid carcinoma. Their reported prevalenc...
OBJECTIVE: The activation of RET proto-oncogene, through different types of chromosomal translocatio...
Objective: The activation of RET proto-oncogene, through different types of chromosomal transloca-ti...
OBJECTIVE: RET proto-oncogene rearrangements (ret/PTCs) represent the most common genetic alteration...
The rearranged during transfection (RET) proto-oncogene was identified in 1985 and, very soon therea...
Thyroid carcinoma is the most frequent endocrine cancer accounting for 5-10% of thyroid nodules. Pap...
We have recently reported the activation of a new oncogene in human papillary thyroid carcinomas. Th...
Non-thyroid neoplasia were analysed by Southern blot of genomic DNA and DNA prepared by reverse tran...
RET proto-oncogene rearrangements (RET/PTC) are causative events in the pathogenesis of a subset of ...
Papillary thyroid carcinomas (PTCs) are the most frequent type of malignant thyroid tumors. Somatic ...
Background: The molecular pathogenesis of hereditary medullary thyroid carcinoma is well known to be...
Malignant tumors of the thyroid gland vary considerably in aggressiveness, ranging from a well-diffe...
The RET/PTC oncogene has been isolated almost twenty years ago. During these years, the research has...
PubMed ID: 18393128Objective: In recent years, thyroid cancer has been at the forefront of molecular...